Saturday 21 December 2024

The Pharma Letter Podcast — Episode 21 — Will radical new EU regs hobble industry?

Pharmaceutical
Simon Wentworth
31 March 2023
podcast-21-big

More on this story...

Pharmaceutical
EC plans would 'sabotage' pharma industry, trade group says
13 February 2023
Biotechnology
European regulator enhances warning on JAK blocker safety
31 March 2023
Biotechnology
Europe follows USA in approving Sotyktu
28 March 2023
Pharmaceutical
European regulatory shake-up fails to impress, as expected
26 April 2023


More ones to watch >


Today's issue

Neurocrine Biosciences launches Crenessity in USA
Pharmaceutical
Neurocrine Biosciences launches Crenessity in USA
20 December 2024
Biotechnology
Epitopea teams up with Genevant in $124 million deal
20 December 2024
Biotechnology
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Biotechnology
Regeneron advances anticoagulant antibody program
20 December 2024
Pharmaceutical
Zealand blindsided by FDA rejection of glepaglutide
20 December 2024
Biotechnology
Astellas partners with Sangamo on cutting-edge gene therapy
20 December 2024
Biotechnology
Novartis to shut MorphSys sites amid pelabresib delay
20 December 2024

Company Spotlight

Australian regenerative medicine company Mesoblast (ASX: MSB) is developing biotherapeutics based on its proprietary cell-based technologies.




More Features in Pharmaceutical

Neurocrine Biosciences launches Crenessity in USA
20 December 2024
Zealand blindsided by FDA rejection of glepaglutide
20 December 2024
Novo Nordisk touts CagriSema success, but results miss expectations
20 December 2024
FDA approves Ionis’ Tryngolza
20 December 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze